The European Medicines Agency this week recommend that seven new drugs be awarded pan-EU marketing approval, including Rivaroxaban Accord (rivaroxaban), which appears to be the first generic version of Bayer’s blockbuster anticoagulant Xarelto to go through the agency’s centralized approval pathway.
Also recommended for approval were two vaccines from Sanofi – MenQuadfi, for prophylaxis against invasive meningococcal disease, and Supemtek...








